A detailed history of Moloney Securities Asset Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Moloney Securities Asset Management, LLC holds 1,882 shares of VRTX stock, worth $848,725. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,882
Previous 1,954 3.68%
Holding current value
$848,725
Previous $915,000 4.37%
% of portfolio
0.12%
Previous 0.14%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$460.0 - $505.78 $33,120 - $36,416
-72 Reduced 3.68%
1,882 $875,000
Q2 2024

Jul 30, 2024

SELL
$392.81 - $485.53 $4,320 - $5,340
-11 Reduced 0.56%
1,954 $915,000
Q1 2024

May 01, 2024

SELL
$407.69 - $446.08 $2,853 - $3,122
-7 Reduced 0.35%
1,965 $821,000
Q4 2023

Jan 30, 2024

SELL
$343.0 - $410.68 $113,190 - $135,524
-330 Reduced 14.34%
1,972 $802,000
Q3 2023

Oct 31, 2023

SELL
$338.18 - $362.46 $827,526 - $886,939
-2,447 Reduced 51.53%
2,302 $800,000
Q2 2023

Jul 31, 2023

SELL
$314.42 - $351.91 $78,290 - $87,625
-249 Reduced 4.98%
4,749 $1.67 Million
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $19,542 - $22,293
-69 Reduced 1.36%
4,998 $1.57 Million
Q4 2022

Jan 30, 2023

SELL
$285.76 - $321.48 $54,294 - $61,081
-190 Reduced 3.61%
5,067 $1.46 Million
Q3 2022

Oct 31, 2022

BUY
$273.83 - $305.53 $547 - $611
2 Added 0.04%
5,257 $1.52 Million
Q2 2022

Aug 03, 2022

SELL
$234.96 - $292.55 $123,354 - $153,588
-525 Reduced 9.08%
5,255 $1.48 Million
Q1 2022

May 10, 2022

SELL
$221.42 - $260.97 $302,016 - $355,963
-1,364 Reduced 19.09%
5,780 $1.51 Million
Q4 2021

Jan 28, 2022

BUY
$177.01 - $223.45 $1.26 Million - $1.6 Million
7,144 New
7,144 $1.57 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Moloney Securities Asset Management, LLC Portfolio

Follow Moloney Securities Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moloney Securities Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moloney Securities Asset Management, LLC with notifications on news.